Form 8-K - Current report:
SEC Accession No. 0001193125-24-271540
Filing Date
2024-12-05
Accepted
2024-12-05 16:18:33
Documents
19
Period of Report
2024-12-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d865739d8k.htm   iXBRL 8-K 33355
2 EX-1.1 d865739dex11.htm EX-1.1 296349
3 EX-4.1 d865739dex41.htm EX-4.1 76897
4 EX-5.1 d865739dex51.htm EX-5.1 19291
9 GRAPHIC g865739g1205141824428.jpg GRAPHIC 1355
10 GRAPHIC g865739snap1.jpg GRAPHIC 4037
  Complete submission text file 0001193125-24-271540.txt   700490

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rvmdw-20241203.xsd EX-101.SCH 4426
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvmdw-20241203_def.xml EX-101.DEF 13415
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvmdw-20241203_lab.xml EX-101.LAB 22307
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvmdw-20241203_pre.xml EX-101.PRE 14319
21 EXTRACTED XBRL INSTANCE DOCUMENT d865739d8k_htm.xml XML 5898
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

EIN.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39219 | Film No.: 241529340
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)